Information  X 
Enter a valid email address

Antisoma PLC (SRC)

  Print      Mail a friend       Annual reports

Tuesday 08 January, 2002

Antisoma PLC


Antisoma PLC
8 January 2002

          Antisoma appoints Lloyd Kelland as Head of Laboratory

London, 8 January 2002 - Antisoma plc (LSE:ASM, NASD:ASOM),  the UK-based
biopharmaceutical company specialising in the development of products for the
treatment of cancer, today announces the appointment of Dr Lloyd Kelland as
Head of Laboratory.

Dr Kelland, joins Antisoma from the UK's Cancer Research Campaign (CRC) Centre
for Cancer Therapeutics, Institute of Cancer Research, London, where he was
Reader/Associate Professor and head of drug evaluation.  Dr Kelland is an
internationally recognised authority in the fields of platinum and other small
molecule anti-cancer agents.

In his new role he will oversee academic and other collaborations linked to
Antisoma's rapidly expanding pre-clinical pipeline.  The Company currently has
four products in clinical trials and five at the pre-clinical stage as well as
a number of highly innovative research programmes.

Dr Kelland, 43, has a degree in Pharmacy and a PhD and Doctor of Science from
the University of Bath, England.  His studies at the CRC Centre for Cancer
Therapeutics have included extensive work on platinum complexes, including
drugs subsequently licensed to Bristol Myers Squibb and AstraZeneca.  He
organised the Eighth International Symposium on Platinum Complexes in 1999 and
is co-author of the book Platinum-based Drugs in Cancer Therapy, published in
2000.  He has recently worked on collaborations linked to the inhibition of
telomerase, farnesyl transferase and various kinases.  Dr Kelland is
vice-chair of the Screening and Pharmacology Group of the European
Organisation for the Research and Treatment of Cancer (EORTC), a member of the
EORTC Laboratory liaison committee and sits on the Editorial Board of the
European Journal of Cancer and Cancer Chemotherapy Pharmacology.  Dr Kelland
is the author or co-author of over 140 peer-reviewed publications.

Glyn Edwards, Antisoma's Chief Executive Officer, commented:

'Lloyd Kelland's appointment reflects the significant and continuing expansion
of Antisoma's pipeline.  We now have four clinical and five pre-clinical
projects.  We also have a highly active in-licensing programme which has
resulted in the acquisition in the past few months of DMXAA, a vascular
targeting agent, and TheraNase, now part of our targeted apoptosis programme.
Dr Kelland brings invaluable expertise and experience to Antisoma at an
important stage of our development.'

- ENDS -


Antisoma plc
Glyn Edwards, Chief Executive Officer           Tel: +44 (0)20 8799 8200

Financial Dynamics
Melanie Toyne Sewell/ Fiona Noblet              Tel: +44 (0)20 7831 3113

Except for the historical information presented, certain matters discussed in
this statement are forward looking statements that are subject to a number of
risks and uncertainties that could cause actual results to differ materially
from results, performance or achievements expressed or implied by such
statements. These risks and uncertainties may be associated with product
discovery and development, including statements regarding the company's
clinical development programmes, the expected timing of clinical trials and
regulatory filings. Such statements are based on management's current
expectations, but actual results may differ materially.

Notes to Editors


Antisoma is a biopharmaceutical company developing novel products for the
treatment of cancer.  Using its drug development experience, the Company aims
to produce safer and more effective tumour targeting therapies for
commercialisation by pharmaceutical partners.  Antisoma acquires the rights to
promising new product candidates through partnerships with internationally
recognised academic or cancer research institutions.  These include the lead
product candidate, pemtumomab, which was licensed from the Imperial Cancer
Research Fund and is currently in a Phase III study as adjuvant treatment for
ovarian cancer, with designated Orphan Drug status in the US and EU.  There
are three additional products in the clinical pipeline, Therex, DMXAA and
TheraFab, and several pre-clinical programmes of which two, Angiomab and
Thioplatin, are expected to enter clinical studies in 2002.  Visit for further information about Antisoma.